Germany · Delayed Price · Currency is EUR Fresenius SE & Co. KGaA Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 5% organic revenue and 13% core EPS growth, with strong contributions from Kabi and Helios. Balance sheet strength improved, S&P upgraded the credit outlook, and full-year guidance was reconfirmed amid ongoing geopolitical and regulatory uncertainty.
-
Healthcare trends and portfolio focus have driven growth, with streamlined operations, innovation, and disciplined capital allocation improving margins and returns. Key segments like IV generics, nutrition, MedTech, and biosimilars are positioned for further expansion, while regulatory and market shifts are being navigated through targeted investment and digitalization.
Fiscal Year 2025
-
Strong 2025 results featured 7% organic revenue and double-digit core EPS growth, with robust Q4 performance and improved leverage. 2026 guidance targets 4%-7% organic revenue growth and 5%-10% core EPS growth, supported by innovation, digitalization, and disciplined capital allocation.
-
Biopharma is positioned as a core growth driver, targeting to double revenue and reach 20% EBIT margin by 2030 through a vertically integrated model, robust pipeline, and global commercial expansion. Strategic investments in R&D and manufacturing, combined with disciplined capital allocation, underpin confidence in long-term profitable growth.
-
Raised EBIT growth guidance to 4%-8% at constant currency, driven by strong execution, 14% EPS growth, and robust performance in Kabi and Helios. Continued deleveraging, targeted investments, and innovation underpin positive outlook into 2026.
-
Strong H1 2025 results with 8% core EPS growth and upgraded revenue guidance to 5-7%, driven by robust performance at Kabi and Helios. Key launches in biosimilars, disciplined capital allocation, and resilience amid macroeconomic and FX headwinds support a positive outlook.
-
The AGM highlighted strong financial growth, significant debt reduction, and a doubling of share price since 2022. Strategic initiatives include the Rejuvenate phase, investments in innovation, and a new dividend policy. Key risks such as geopolitical uncertainty and workforce shortages were addressed.
-
Q1 2025 saw strong organic revenue and EBIT growth, with double-digit EPS gains and robust cash flow. CABI and Helios delivered solid margins, biopharma expanded rapidly, and deleveraging continued. Full-year guidance is maintained despite expected Q2 headwinds.
-
A comprehensive transformation has streamlined operations, improved financials, and focused growth on clinical nutrition, medical technology, and biopharma, with Tyenne and other biosimilars driving innovation. Margin expansion, disciplined capital allocation, and a cautious China outlook shape the 2025 strategy.
Fiscal Year 2024
-
Strong 2024 results featured high single-digit organic revenue and double-digit EBIT growth, driven by Kabi's growth vectors and structural improvements. 2025 guidance anticipates continued revenue and EBIT growth, with key headwinds in China and Germany, and a renewed focus on innovation and margin expansion.
-
Q3 2024 saw strong organic revenue and earnings growth, driven by robust performances at Kabi and Helios, with significant cash flow and margin improvements. Upgraded guidance reflects confidence despite headwinds from China, lower biopharma milestone payments, and loss of energy relief funding.
-
Strong Q2 and H1 2024 results with 8% organic revenue growth, 15% EBIT increase, and robust cash flow drove leverage down to target levels. Kabi and Helios segments excelled, while cost savings and innovation supported margin expansion. China remains a headwind.
-
Future Fresenius strategy has delivered a simpler, stronger group focused on organic growth, operational excellence, and digital innovation. Upgraded financial targets include 4%-6% annual revenue growth and a 10%-12% EBIT margin by 2027, with both Germany and Spain contributing. Regulatory changes and digitalization are seen as opportunities for further margin and quality gains.